Background: The VELOUR randomized placebo-controlled phase III trial established aflibercept combined with FOLFIRI as an effective regimen in metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen. Health-related quality of life (HRQoL) was not evaluated in VELOUR trial. Methods: The current study prospectively evaluated the impact on HRQoL (using the Functional Assessment of Cancer Therapy-Colorectal - FACT-C scale), the effectiveness, and tolerability of aflibercept plus FOLFIRI prescribed in Bulgarian patients with mCRC in daily clinical practice.
📖 افتح في inklap 🔗 DOI 📮 اطلب بحثاً